Vasculitis & polymyalgia rheumatica
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis
Authors' conclusion
Targeting the interleukin-5 receptor with benralizumab or circulating interleukin-5 with mepolizumab are effective OGC-sparing strategies in patients with EGPA.
Study context
- Population
- Adults with eosinophilic granulomatosis with polyangiitis (EGPA) requiring ≥7.5 mg/day OGC with or without immunosuppressive therapy
- Participants
- 70 vs 70
- Comparison
- Benralizumab 30 mg vs mepolizumab 300 mg SC every 4 weeks for 52 weeks
- Benralizumabn = 70
- Mepolizumabn = 70reference
Methodological detailsphase 3, Investigators tapered oral glucocorticoids (OGCs) for patients with stable EGPA based on clinical judgment
- Phase 3
- Investigators tapered OGCs for patients with stable EGPA based on clinical judgment
Primary result
As reported in the abstract
OGC use: cumulative dose and median dose · weeks 49 to 52
Further findings
Events
| Outcome | Benralizumab | Mepolizumab | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Complete OGC withdrawal (time to first) | 33 | 20 | 1.84 (1.06–3.27) | unstratified log-rank test P = 0.0291 | |
| Sustained complete OGC withdrawal · by week 40, maintained through week 52 | 17 | 7 | 2.97 (1.26–7.77) | unstratified log-rank test P = 0.0268 | |
| 0.10.31310Hazard ratio (log scale) |
Time to first or sustained OGC reduction to ≤4 mg/day or by ≥50%; accrued OGC-free duration
- Similar between groups
Complete OGC withdrawal across subgroups (incl. ANCA status, immunosuppressive use)
- Similar across patient subgroups in both groups
Original publication
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol. Published 30 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →